TASK DEFINITION: Given a paragraph, generate a claim that is supported by the given paragraph. 1) The claim must contain information from within the paragraph. 2) A sentence within the paragraph can be used as a claim. 3) The claim should not have contradictions within the paragraph. 4) The claim should be at most one sentence long.
PROBLEM: "Florida leads the nation in deaths from lightning strikes. But State Farm, one of the nation’s major insurers, says it is Georgia residents who file the most claims for lightning strikes in the country, WSB-TV reported Friday, June 5. PolitiFact Georgia was intrigued and decided to dig a little deeper. We began by contacting Justin Tomczak, a State Farm spokesman. He sent us data showing Georgia was No. 1 in 2014 for lightning-related claims both in number (3,709) and total dollar value ($16.3 million). Texas was second, Alabama at third, Louisiana at fourth and Illinois at fifth. STATE Reported Count Paid Indemnity  Georgia 3,709 $16,301,952 Texas 2,201 $14,160,258 Alabama 1,902 $10,930,264 Louisiana 1,707 $10,930,264 Illinois 1,669 $8,030,507 . ""This is the third year in a row that Georgia has been ranked No. 1,"" Tomczak said. Most of the lightning claims were surge- or power-related, the spokesman said. Damages generally resulted from power surges in electrical wiring, TV cable or phone lines in homes or businesses, he said. As to why Georgia has the most claims, Tomczak said, ""there is no simple answer. However, many of the lightning claims are concentrated in the Southeastern United States, and Georgia has one of the highest populations in this area."" John Jensenius, lightning safety specialist with the National Weather Service, said the population density in metro Atlanta may be a factor in Georgia’s high claim rate. The denser the population the more likely lightning will strike a house, Jensenius said. The Insurance Information Institute, in conjunction with State Farm, compiles a list each year of the top 10 states for homeowners insurance lightning losses by number of claims. In 2013, the institute listed Georgia as highest with 11,184 lightning-related insurance claims from homeowners. Its 2014 report is due out within days, a spokeswoman said. (Georgia was No. 1 for 2012 with 3,844 claims totalling $21.5 million and for 2013 with 2,969 claims totalling $14.9 million, according to State Farm). Nationwide, lightning strikes cost about $674 million in homeowners insurance losses in 2013, down 30.5 percent from 2012, according to the institute. From 2007 to 2011, local fire departments across the country responded to an average of 22,600 fires a year that were started by lightning, according to the National Fire Protection Association. These fires caused an average of $451 million in direct property damage and nine civilian deaths a year, an NFPA analysis shows. Lightning deaths  Florida led the nation for lightning deaths in 2014 with six, followed by Wisconsin with three. Georgia, Arizona, Arkansas, Colorado and Massachusetts each had two deaths. Seven additional states -- California, Michigan, Missouri, Mississippi, New Mexico, Pennsylvania and Texas -- reported one lightning death in the year. The 26 lightning deaths in 2014 followed a record low of 23 set in 2013. The National Weather Service said deaths from lightning strikes averaged 33 a year from 2004 to 2013 and, going back over the last 30 years, an average of 51 people died each year after being hit by lightning. The significant decline in lightning deaths has been attributed to fewer farmers working in the fields, technological advances, improved safety standards and protection. As of the June 1, 2015 there have been six lightning fatalities, two in North Carolina and one each in Iowa, Florida, New Mexico and West Virginia, according to the National Oceanic and Atmospheric Administration (NOAA). WSB-TV meteorologist Brian Monahan said lightning strikes occur most often in Georgia during the summer months when the high pressure area out in the Atlantic around Bermuda pumps in warm, humid air, creating those all-too-familiar afternoon and evening thunderstorms. A secondary spike of lightning strikes also occurs in the severe weather seasons of March to early May and around October and November, when the air is still warm and humid enough to support storms, Monahan said. Our ruling State Farm says Georgia residents file the most claims for lightning strikes in the country. There’s evidence this has been the case last year and the two previous years."

SOLUTION: Georgia residents file the most insurance claims for lightning strikes in the country.

PROBLEM: The story mentioned that the cost of this drug treatment was several thousand dollars a month and that this was higher than the costs of other treatments. It would have been better to provide a more concrete estimate of costs (several thousand – does this mean 2,3 or 6 thousand?). The story might have included some information about additional costs that would be encountered with the comparison treatment such as the cost of intraveneous infusions, testing to  evaluate side-effects, and other connected costs. The story did a good job reporting the data comparing patient survival with Iressa as compared to individuals treated with IV chemotherapy. The story skimmed over the side effects; reducing the frequency of bothersome or life threatening side effects would seem to be an advantage. The story mentioned quality of life factors that appear to be better with Iressa but did not  quantify the benefit observed. Borderline satisfactory. The story listed the common side effects of the treatment though it failed to indicate the frequency with which these were seen. In addition, rather than than merely listing these, the story could have included some information about the severity of the side effects (i.e. bothersome vs. fatal). The story provided information about the size of the study conducted, the nature of the patients that were enrolled, and that the drug company that markets the drug funded the study. The study was designed as a non-inferiority survival trial to compare this medication with docotaxel, a chemotherapy treatment often used in individuals who have lung cancer and have had platinum based treatment but who are experiencing a return of their cancer. (While the story did provide information about the survival outcomes, it also included information comparing side effects.) The story ended with a comment from one of the interviewed clinicians about quality of life being better with Iressa. The story should have been clearer about the predetermined endpoint of the study (longevity) and should not have ended with less data driven information. The story did not engage in overt disease mongering. However the headline does not hint that the trial is not about first-line cancer treatment, rather just patients who have been treated previously with a platinum-based chemotherapy. The story included quotes from two individuals identified as not being connected with the study reported upon but with relevant expertise. The story provided information about two treatment options for individuals who have recurrence of a previously treated lung cancer. It did not provide information about the natural history of not undergoing additional treatment for this condition which is necessary for evaluating the relative merit of the two treatments discussed. The story did not mention radiation and surgery which are both options for some limited cancers. The story mentions that the medication Iressa (gefitinib) is sold in the United States but that its availability in Europe is limited. The story presented the use of Iressa as a treatment of individuals with lung cancer who had previously been treated with a platinum-based regimen as though it was a novel application. However – this drug was approved by the FDA in 2003 for this purpose. While the results of study reported on are interesting, the story did not provide the reader with a realistic picture of about the novelty of this product. Does not appear to rely on a press release.

SOLUTION: Pill as good as chemo on lung cancer, but costlier

PROBLEM: Although there was no discussion of costs, the article was clear in stating that vaccines are for the most part in an early stage of development, so this omission is understandable. We wanted to see better coverage of the data here. The story leads with an anecdote about a patient who kicked a pack-a-day smoking habit after treatment with a nicotine vaccine in a study. And later, the story says that smokers who received that vaccine were “about three times as likely to be off cigarettes 44 weeks after vaccination than subjects given a placebo.” The story should have provided the absolute rates of success reported in the study, which were only 16% for the treatment group compared with 6% for the placebo group, according to theheart.org. Elsewhere, the story describes an experimental anticocaine vaccine that was apparently very effective in a mouse study; it could have reported on phase II human data that is available for the TA-CD anticocaine vaccine that was also mentioned in the story. These data again suggest that only a minority of patients may benefit from the use of anti-addiction vaccines. The story states that “clinical trials have so far revealed no significant side effects” from vaccine treatments. However, we think the story should have included an important caveat: that these are early stage trials involving small numbers of patients that can’t provide conclusive evidence of safety. In addition, it should be recognized that addictions are chronic conditions and these vaccine treatments are likely to be long-term as well. Therefore, longer-term adverse effects should be expected, especially for a treatment that interferes with molecules closely related to the body’s natural chemical messengers. The story could have been a bit more circumspect on this point. The promise of this new vaccine technology is counterbalanced by coverage of the uncertainties. The story gives appropriate weight to the disappointing results reported in a number of early clinical studies, noting: “Failures have so far outnumbered successes.” The story adds that even in one of the successful vaccine studies, the benefits were not as robust as those seen with a smoking cessation drug that is already on the market. There also is no prospect for a vaccine to treat alcoholism, according to the story. The article should have been more direct about the limitations of mouse research, and there was not enough detail on the data published in the various studies reported on (a deficiency we address under the “Benefits” criterion). However, since the story was trying to present a broad overview of happenings in the field and wasn’t attempting to summarize any particular study, we’ll give the benefit of the doubt here and award a satisfactory. The story didn’t exaggerate the effects of substance abuse disorders or otherwise engage in disease-mongering. The sourcing of this story was good. We hear from academics, government researchers, and industry executives. Their voices provide balance and give texture to the coverage. It should be noted, however, that most of these experts have a vested interest in the field or the success of a particular treatment, whether because of industry ties or because they are leading experiments on a particular approach. Even the government experts might be biased by their provision of significant financial support for research in this area. It would have been nice to hear a comment about the vaccines from someone who is certifiably free of all potential conflicts. But we can’t justify docking points since there is no voice that is overly enthusiastic about the concept. The story compares the potential of vaccines with the benefits of existing medications for addiction–and notes that the available drugs might work better. We would like to have seen more ink given to the role of behavioral approaches in the management of addiction, which are supported by considerable evidence. However, the story does acknowledge that vaccines “would likely be used alongside psychological therapy.” We’ll call it good enough for a satisfactory. The article helpfully states that “It could be years, if ever, before any vaccines to treat addiction reach the market.” The article does a good job of describing how far along the various experimental vaccines mentioned in the article are in their development. Although the story could have provided more background on the history of anti-addiction vaccines (a heroin vaccine was explored in the 1970s), the treatments being explored now are different from anything currently available. So we don’t think this story overstates the novelty of the research. This story is not based on a news release.

SOLUTION:
Quest for Vaccines to Treat Addiction